Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13729969 | 0.81 | BRD9 (0.46) | MAPKAPK2HTR2AHTR2CHTR2BCA1 | |
| SCHEMBL11657761 | 0.81 | CHRM1 (0.42) | ALDH1A1HTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL315232 | 0.79 | PDE3B (0.41) | MAPKAPK2ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL315233 | 0.79 | PDE3B (0.41) | MAPKAPK2ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL315231 | 0.79 | PDE3B (0.41) | MAPKAPK2ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL12654554 | 0.78 | PARP1 (0.36) | ALDH1A1BRD9ALOX12 | |
| SCHEMBL11658394 | 0.78 | ALDH1A1 (0.53) | ALDH1A1CHRM1BRD4LMNAALOX12 | |
| SCHEMBL31398247 | 0.75 | BRD4 (0.44) | ALDH1A1HTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL11658276 | 0.75 | PDE3B (0.40) | MAPKAPK2ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL13729922 | 0.74 | HTR2C (0.36) | ALDH1A1HTR2AHTR2CCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9422292-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422292-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2705039-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | MAPKAPK2 1656/4885ALDH1A1 3348/4885HTR2A 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.